Company research
NANOVIRICIDES, INC.
CIK 1379006Updated Sep 24, 2026
SecurityNNVC · NYSE_AMERICAN · equity
NNVC price & chart
Loading TradingView…
AMEX:NNVC on TradingView ↗About the company
NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an “Orphan Drug Designation” (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at “first visit” when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
424B3 filing
EFFECT filing
S-3 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,824,085Source | 12,822,853Source | 16,899,880Source | 23,494,862Source |
| Property, Plant and Equipment, NetUSD | 6,833,891Source | 7,512,463Source | 8,106,647Source | 8,694,194Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 317,039Source | 325,308Source | 333,578Source | 341,848Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,558,564Source | 4,797,778Source | 8,149,808Source | 14,066,359Source |
| Assets, CurrentUSD | 1,670,710Source | 4,970,520Source | 8,445,294Source | 14,416,380Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,300,000Source | 1,358,776Source | 2,034,250Source | — |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 166Source | 131Source | 116Source | 11,592Source |
| Additional Paid in CapitalUSD | 156,359,252Source | 150,838,832Source | 145,946,258Source | 145,562,124Source |
| Retained Earnings (Accumulated Deficit)USD | -148,841,861Source | -139,374,895Source | -131,080,749Source | -122,492,176Source |
| Stockholders' Equity Attributable to ParentUSD | 7,517,566Source | 11,464,077Source | 14,865,630Source | 23,082,025Source |
| Liabilities and EquityUSD | 8,824,085Source | 12,822,853Source | 16,899,880Source | 23,494,862Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,306,519Source | 1,358,776Source | 534,250Source | 412,837Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 25,969Source | 262,467Source | 143,760Source | 45,692Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -9,466,966Source | -8,294,146Source | -8,588,573Source | -8,106,863Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,478,679Source | -6,315,507Source | -5,670,051Source | -5,891,254Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -56,964Source | -156,560Source | -151,712Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 56,964Source | 156,560Source | 151,712Source | 324,348Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,296,429Source | 3,120,037Source | -94,788Source | -234,716Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,558,564Source | 4,797,778Source | 8,149,808Source | 14,066,359Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 149Source | — | 938Source | 5,123Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 563Source | 44,000Source | — |
| Amortization of Intangible AssetsUSD | 8,269Source | 8,270Source | 8,270Source | 8,270Source |
| DepreciationUSD | 735,536Source | 750,744Source | 739,259Source | 715,055Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 4,042,544Source | 3,078,814Source | 2,551,054Source | 2,328,737Source |
| InterestExpenseNonoperatingUSD | 149Source | 49,808Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -9,466,966Source | -8,294,146Source | -8,588,573Source | -8,106,863Source |
| Nonoperating Income (Expense)USD | 124,679Source | 221,965Source | 354,895Source | 6,736Source |
| Operating ExpensesUSD | 9,591,645Source | 8,516,111Source | 8,943,468Source | 8,113,599Source |
| Other Nonoperating Income (Expense)USD | 124,828Source | 271,773Source | 355,833Source | 11,859Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 0Source | 0Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -9,591,645Source | -8,516,111Source | -8,943,468Source | -8,113,599Source |
| Other Nonoperating Income (Expense)USD | 124,828Source | 271,773Source | 355,833Source | 11,859Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -8,106,863Source |
| Net Income (Loss) Attributable to ParentUSD | -9,466,966Source | -8,294,146Source | -8,588,573Source | -8,106,863Source |
| Earnings Per Share, BasicUSD per share | -0.63Source | -0.7Source | -0.74Source | -0.7Source |
| Earnings Per Share, DilutedUSD per share | -0.63Source | -0.7Source | -0.74Source | -0.7Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,116,548Source | 11,871,054Source | 11,626,220Source | 11,534,698Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,116,548Source | 11,871,054Source | 11,626,220Source | 11,534,698Source |
| Interest Expense (non-operating)USD | 149Source | 49,808Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 8,269Source | 8,270Source | 8,270Source | 8,270Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 4,042,544Source | 3,078,814Source | 2,551,054Source | 2,328,737Source |
| Interest ExpenseUSD | — | — | 938Source | 5,123Source |
| Interest Expense, DebtUSD | — | 49,808Source | — | 5,123Source |
| Nonoperating Income (Expense)USD | 124,679Source | 221,965Source | 354,895Source | 6,736Source |
| Operating ExpensesUSD | 9,591,645Source | 8,516,111Source | 8,943,468Source | 8,113,599Source |
| Research and Development ExpenseUSD | 5,549,101Source | 5,437,297Source | 6,392,414Source | 5,784,862Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 0Source | 0Source | — |
Filing attachments
tm2621493d1_ex4-1.htm · 8-K · 2026-07-30
EX-4.1 2 tm2621493d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Nanoviricides, INC. Warrant Shares: [ ] Initial Exercise Date: July [ ], 2026 ────────────────────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter s…
Read attachment ↗tm2621493d1_ex4-2.htm · 8-K · 2026-07-30
EX-4.2 3 tm2621493d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗tm2621493d1_ex99-1.htm · 8-K · 2026-07-30
EX-99.1 8 tm2621493d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering New York, July 24, 2026 - NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with …
Read attachment ↗tm2615013d1_ex4-1.htm · 8-K · 2026-05-20
EX-4.1 2 tm2615013d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Nanoviricides, INC. Warrant Shares: 200,000 Initial Exercise Date: May 18, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Ex…
Read attachment ↗tm2615013d1_ex4-2.htm · 8-K · 2026-05-20
EX-4.2 3 tm2615013d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT…
Read attachment ↗tm2615013d1_ex99-1.htm · 8-K · 2026-05-20
EX-99.1 8 tm2615013d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering SHELTON, CT Friday, May 15, 2026 NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement …
Read attachment ↗